Sign Up Today and Learn More About Casma Therapeutics Stock
Invest in or calculate the value of your shares in Casma Therapeutics or other pre-IPO companies through EquityZen's platform.
Casma Therapeutics Stock (CATH)
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
About Casma Therapeutics Stock
Founded
2017
Headquarters
Cambridge, MA, US
Industries
Science and Engineering, Health Care, Biotechnology
Casma Therapeutics Press Mentions
Stay in the know about the latest news on Casma Therapeutics
Bifunctional degraders and uses thereof
patents • Apr 02, 2025
Trpml modulators
patents • Feb 08, 2025
Casma Therapeutics discovers new AUTACS
bioworld • Dec 28, 2024
Methods of tfeb activation and lysosomal biogenesis and compositions therefor
patents • Apr 14, 2024
Biomarkers of trpml1 activation
patents • Apr 14, 2024
Casma Therapeutics Management
Leadership team at Casma Therapeutics
Board Member
Hiromichi Kimura
Board Of Director
Frank T. Gentile
Join now and verify your accreditation status to gain access to:
- Casma Therapeutics Current Valuation
- Casma Therapeutics Stock Price
- Casma Therapeutics Management
- Available deals in Casma Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Casma Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Casma Therapeutics Revenue and Financials
- Casma Therapeutics Highlights
- Casma Therapeutics Business Model
- Casma Therapeutics Risk Factors
- Casma Therapeutics Research Report from SACRA Research
Trading Casma Therapeutics Stock
How to invest in Casma Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Casma Therapeutics through EquityZen funds. These investments are made available by existing Casma Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Casma Therapeutics stock?
Shareholders can sell their Casma Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
